Mobilaser Study to Help With People Who Are Having Problems With Their Gait

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jay A. Van Gerpen, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01581645
First received: November 10, 2011
Last updated: February 12, 2014
Last verified: February 2014
  Purpose

Does use of the Mobilaser reduce freezing of gait (FOG) and stride reduction in patients with Parkinson's disease and Parkinsonism.


Condition Intervention
Parkinson's Disease
Parkinsonism
Device: Mobilaser

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Increasing Mobility in Parkinsonian Patients With Freezing of Gait and Gait Hypokinesia With an Adjustable, Attachable Laser (Mobilaser)

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Improvement in Gait [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: May 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Mobilaser
    Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
    Other Names:
    • Laser
    • Walker with laser
Detailed Description:

Can patients walk faster and have less freezing when using the mobilaser then when not using it

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion

  • Parkinsonian patients with Freezing of Gait or Gait hesitation.
  • Must have evidence of bradykinesia ambulating (stride reduction or reduced arm swing)
  • Must have a constant caregiver

Exclusion

  • No cardiopulmonary contraindications to ambulation, e.g., unstable angina pectoris;
  • Severe arthritis;
  • Cerebellar or sensory ataxia;
  • Recent knee or hip surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01581645

Locations
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Jay Van Gerpen, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Jay A. Van Gerpen, Assistant Professor of Neurology, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01581645     History of Changes
Other Study ID Numbers: 10-002978
Study First Received: November 10, 2011
Last Updated: February 12, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Parkinson's disease
Parkinsonism
Gait problems
Freezing gait

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on April 17, 2014